Law Offices of Howard G. Smith announces an investigation on behalf of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims & Hers Health, Inc. (“Hims”) and its weight loss drug, Wegovy, would no longer be available through Hims, stating that Hims “has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization’ and are disseminating deceptive marketing that put patient safety at risk.”

On this news, Novo Nordisk’s stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Novo Nordisk securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250625920192/en/